5 months from ethics approval to first dosing in P1a.
13 months to complete P1a - although only recruited 14 from a planned 19-28 patients (later reported that one patient died from PD1-Vaxx induced Immune-mediated pneumonitis).
18 months later, the first patient is dosed in the combination P1b arm - could it be that investigators were concerned regarding the grade 5 toxicity?
No update has been provided on the PD1-Vaxx trial since this update in June 2023, however the trial was updated on clinicaltrials.gov in November 2024 to show 'not recruiting'. Only 10 patients have been recruited in the P1b combination therapy arm.
IMU Price at posting:
3.6¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)